Overview
Swedish MedTech firm's Q4 revenue declined 3.9% yr/yr, net sales rose 9.7% currency-adjusted
Q4 operating profit improved to SEK 13.0 mln from SEK -3.2 mln
Company's Q4 EBITDA rose to SEK 24.7 mln from SEK 8.4 mln
Outlook
Bactiguard aims for double-digit revenue growth in Wound Management portfolio in 2026
Company plans to secure additional partnerships and support existing partners in 2026
Bactiguard to enhance operational efficiency to support growth and profitability
Result Drivers
ZIMMER BIOMET AGREEMENT - Updated agreement with Zimmer Biomet boosted Q4 revenue and profitability in license business
HYDROCYN AQUA GROWTH - Double-digit growth in Hydrocyn aqua product line offset declines in other areas
CURRENCY IMPACT - Total revenue negatively impacted by US dollar exchange rates and discontinued products
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue | Beat | SEK 65.60 mln | SEK 51 mln (1 Analyst) |
Q4 Adjusted EPS | SEK 0.36 | ||
Q4 Net Income | SEK 12.50 mln | ||
Q4 EBITDA | SEK 24.70 mln | ||
Q4 Operating Cash Flow | SEK 11.70 mln | ||
Q4 Operating Profit | SEK 13 mln |
Analyst Coverage
The one available analyst rating on the shares is "hold"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for Bactiguard Holding AB is SEK26.25, about 76.8% above its February 4 closing price of SEK14.85
Press Release: ID:nWkrbhS21N
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)